Kanaph Therapeutics is a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules.
Kanaph Therapeutics has raised $17.8M in total funding. The most recent round was Series C. The last funding was announced in December 2023.
Kanaph Therapeutics's investors include InterVest Co., Premier Partners, LOTTE Biologics, Aju IB Investment, Dayli Partners.
Kanaph Therapeutics is headquartered in Yongsan, South Korea.
Kanaph Therapeutics is a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules.
Kanaph Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kanaph Therapeutics — Funding & Investors." VCBacked, December 27, 2023, https://www.vcbacked.co/company/kanaph-therapeutics. Accessed July 31, 2026.
VCBacked. (2023). Kanaph Therapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/kanaph-therapeutics
{{cite web |title=Kanaph Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kanaph-therapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated